期刊文献+

肝脏门静脉期CT增强的影响因素与对策 被引量:6

Contrast enhancement of abdominal CT at portal venous phase:considerations and solutions
下载PDF
导出
摘要 随着CT技术的发展,尤其是近几年双能CT的出现,不仅提高了影像质量,而且能够实现物质定量分析,极大拓展了临床应用范围,但同时也对优化应用提出了新的挑战。在上腹部检查中由于肝脏双重供血的特点造成了增强检查的特殊性,这突出体现在门静脉期影像质量难以达到预期而降低诊断可靠性上。因此,分析影响门静脉期增强的对比剂、病人和CT扫描等方面因素,总结在提高影像质量的同时降低对比剂剂量和辐射剂量的研究进展,并展望基于双能CT的个性化的上腹部增强检查计划设计方案。 With the continuing development of computed tomographic (CT) technology, especially dual-energy CT (DECT), new clinical applications has been discovered based on the capability of material decomposition and improved image quality accordingly. Innovative CT technology has introduced new challenges in optimization of clinical radiology practice in return. One of the challenges is with contrast enhancement of upper abdominal CT at portal venous phase which is difficult to optimize due to the double blood supply. In this article, contrast medium, patient and CT scanning factors associated with contrast enhancement at portal venous phase were addressed and discussed. Published studies on improving image quality while reducing contrast medium dose and radiation dose were reviewed and interpreted. A new paradigm of individualized examination planning system based on dual-energy CT to optimize contrast medium administration and scanning protocol was proposed.
作者 杨克柽 陈伟
出处 《国际医学放射学杂志》 2015年第6期562-566,571,共6页 International Journal of Medical Radiology
基金 全军医学科技"十二五"重点课题(BWS11J015) 第三军医大学第一附属医院转化医学合作课题(SWH2014ZH04)
关键词 体层摄影术 X线计算机 双能量CT 门静脉期 对比剂 CT Tomography,X-ray computed Dual-energy CT Portal venous phase Contrast medium
  • 相关文献

参考文献44

  • 1Geenen RW, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention [J]. Insights Imaging, 2013, 4:811-820.
  • 2Bae KT, Heiken JP, Brink JA. Aortic and hepatic contrast medium enhancement at CT. | . Prediction with a computer model[J]. Radiology, 1998, 207:647-655.
  • 3Bae KT. Peak contrast enhancement in CT and MR angiography: when does it occur and why? Pharmacokinetic study in a porcine model[J]. Radiology, 2003, 227:809-816.
  • 4Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches [J]. Radiology, 2010, 256:32-61.
  • 5Amato E, Salamone I, Naso S, et al. Can contrast media increase organ doses in CT examinations? A clinical study[J]. AJR, 2013, 200:1288-1293.
  • 6Bae KT, Seeck BA, Hildeboh CF, et al. Contrast enhancement in cardiovascular MDCT: effect of body weight, height, body surface area, body mass index, and obesity[J]. AJR, 2008, 190:777-784.
  • 7Kondo H, Kanematsu M, Goshima S, et al. Body size indices to determine iodine mass with contrast-enhanced multi-detector computed tomography of the upper abdomen: does body surface area outperform total body weight or lean body weight [J]. Eur Radiol, 2013, 23:1855-1861.
  • 8Kidoh M, Nakaura T, Oda S, et al. Contrast enhancement during hepatic computed tomography: effect of total body weight, height, body mass index, blood volume, lean body weight, and body surface area[J]. J Comput Assist Tomogr, 2013, 37:159-164.
  • 9Kondo H, Kanematsu M, Goshima S, et al. Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT: comparison of total body weight, lean body weight, and blood volume[J]. Radiology, 2010, 254:163-169.
  • 10Svensson A, Nouhad J, Cederlund K, et al. Hepatic contrast medium enhancement at computed tomography and its correlation with various body size measures[J]. Acta Radiol,2012, 53:601-606.

同被引文献31

引证文献6

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部